Nucleotide excision repair (NER) is a highly conserved DNA repair pathway that functions to protect the genome from the detrimental effects of DNA lesions introduced by endogenous and environmental sources, including UV light. Defects in the NER system result in genomic instability and the development of cancers. The initial step in NER requires lesion recognition, and is performed by the heterodimeric DNA damage binding proteins XPC-HR23B and UV-DDB (composed of the p48 and p127 proteins). The DDB2 (encoding the p48 protein) and XPC genes are transcriptionally induced by the p53 tumor suppressor gene following DNA damage. In addition, both p48 and XPC are post-translationally regulated by the ubiquitin-proteasome degradation pathway. Covalent attachment of mono- and polyubiquitin chains to cellular proteins has emerged as a predominant cellular regulatory mechanism with roles in cell division, signal transduction, endocytic trafficking, and DNA repair. Thus, the DNA damage recognition step of NER is highly regulated through transcriptional and post-transcriptional mechanisms. The long-term objectives of this project are to understand how the ubiquitin-proteasome pathway regulates human NER. The hypothesis is that UV-induced ubiquitination of the NER proteins t>48 and XPC specifically regulate their degradation, protein- and DNA damage binding activities, and affect on NER. These studies will have broad applicability to understanding the role of DNA repair in health and disease, and provide important insight into the role of NER in the etiology of human cancer. The project will be approached through the following specific aims. 1. To determine if the human DNA damage recognition factors p48 and XPC are ubiquitinated and if this process is regulated by HR23B. 2. To determine whether ubiquitination of these NER proteins is required for DNA damage binding activity, in vivo. 3. To determine the functional consequences of ubiquitination on NER activity in human cells.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-CDF-2 (90))
Program Officer
Okano, Paul
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Hastak, Kedar; Alli, Elizabeth; Ford, James M (2010) Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res 70:7970-80
Anders, Carey K; Winer, Eric P; Ford, James M et al. (2010) Poly(ADP-Ribose) polymerase inhibition: ""targeted"" therapy for triple-negative breast cancer. Clin Cancer Res 16:4702-10
Alli, Elizabeth; Sharma, Vandana B; Sunderesakumar, Preethi et al. (2009) Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 69:3589-96
Lin, Patrick S; McPherson, Lisa A; Chen, Aubrey Y et al. (2009) The role of the retinoblastoma/E2F1 tumor suppressor pathway in the lesion recognition step of nucleotide excision repair. DNA Repair (Amst) 8:795-802
Chen, Xiaoai; Zhang, Jianxuan; Lee, Jennifer et al. (2006) A kinase-independent function of c-Abl in promoting proteolytic destruction of damaged DNA binding proteins. Mol Cell 22:489-99